Guggenheim started coverage on shares of Merus (NASDAQ:MRUS) in a report published on Friday, Benzinga’s Daily Ratings Newsletter reports. The firm issued a buy rating and a $25.00 price objective on the biotechnology company’s stock.

Several other research firms have also weighed in on MRUS. Zacks Investment Research lowered shares of Merus from a buy rating to a hold rating in a research note on Wednesday, March 27th. Wedbush dropped their price objective on shares of Merus from $34.00 to $25.00 and set an outperform rating on the stock in a research note on Friday, April 5th. Citigroup dropped their price objective on shares of Merus from $18.00 to $16.00 and set a neutral rating on the stock in a research note on Friday, March 15th. BidaskClub lowered shares of Merus from a hold rating to a sell rating in a research note on Thursday, March 21st. Finally, ValuEngine upgraded shares of Merus from a sell rating to a hold rating in a research note on Wednesday, March 6th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and an average target price of $23.00.

MRUS stock opened at $16.45 on Friday. Merus has a 52-week low of $11.00 and a 52-week high of $26.74. The company has a market cap of $349.21 million, a PE ratio of -8.94 and a beta of -0.06.

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC increased its stake in Merus by 10.3% in the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,100 shares during the period. Geode Capital Management LLC increased its stake in Merus by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 2,373 shares during the period. JPMorgan Chase & Co. increased its stake in Merus by 33.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 4,476 shares during the period. Morgan Stanley increased its stake in Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 30,538 shares during the period. Finally, Artal Group S.A. acquired a new position in Merus in the 4th quarter valued at approximately $2,886,000. Hedge funds and other institutional investors own 53.06% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: What is a trade deficit?

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.